(Q36839786)

16 August 2017

1 reference

title

Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination (English)

1 reference

16 August 2017

main subject

cervix uterine cancer

1 reference

Eduardo L Franco

1

0 references

author name string

Alex Ferenczy

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

319-327

1 reference

The global health burden of infection-associated cancers in the year 2002

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

The epidemiology of genital human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Evaluating human papillomavirus vaccination programs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.319

21 January 2018

Identifiers

DOI

10.2217/14796694.3.3.319

1 reference

16 August 2017

1 reference